107 related articles for article (PubMed ID: 10584562)
1. [Mechanism of occurrence of secondary tumors by antitumor drugs].
Andoh T
Gan To Kagaku Ryoho; 1999 Nov; 26(13):1988-98. PubMed ID: 10584562
[TBL] [Abstract][Full Text] [Related]
2. Near-precise interchromosomal recombination and functional DNA topoisomerase II cleavage sites at MLL and AF-4 genomic breakpoints in treatment-related acute lymphoblastic leukemia with t(4;11) translocation.
Lovett BD; Lo Nigro L; Rappaport EF; Blair IA; Osheroff N; Zheng N; Megonigal MD; Williams WR; Nowell PC; Felix CA
Proc Natl Acad Sci U S A; 2001 Aug; 98(17):9802-7. PubMed ID: 11493704
[TBL] [Abstract][Full Text] [Related]
3. Reciprocal DNA topoisomerase II cleavage events at 5'-TATTA-3' sequences in MLL and AF-9 create homologous single-stranded overhangs that anneal to form der(11) and der(9) genomic breakpoint junctions in treatment-related AML without further processing.
Whitmarsh RJ; Saginario C; Zhuo Y; Hilgenfeld E; Rappaport EF; Megonigal MD; Carroll M; Liu M; Osheroff N; Cheung NK; Slater DJ; Ried T; Knutsen T; Blair IA; Felix CA
Oncogene; 2003 Nov; 22(52):8448-59. PubMed ID: 14627986
[TBL] [Abstract][Full Text] [Related]
4. Secondary leukemias induced by topoisomerase-targeted drugs.
Felix CA
Biochim Biophys Acta; 1998 Oct; 1400(1-3):233-55. PubMed ID: 9748598
[TBL] [Abstract][Full Text] [Related]
5. Detection of leukemia-associated MLL-GAS7 translocation early during chemotherapy with DNA topoisomerase II inhibitors.
Megonigal MD; Cheung NK; Rappaport EF; Nowell PC; Wilson RB; Jones DH; Addya K; Leonard DG; Kushner BH; Williams TM; Lange BJ; Felix CA
Proc Natl Acad Sci U S A; 2000 Mar; 97(6):2814-9. PubMed ID: 10706619
[TBL] [Abstract][Full Text] [Related]
6. Site-specific DNA cleavage within the MLL breakpoint cluster region induced by topoisomerase II inhibitors.
Aplan PD; Chervinsky DS; Stanulla M; Burhans WC
Blood; 1996 Apr; 87(7):2649-58. PubMed ID: 8639880
[TBL] [Abstract][Full Text] [Related]
7. Leukemias related to treatment with DNA topoisomerase II inhibitors.
Felix CA
Med Pediatr Oncol; 2001 May; 36(5):525-35. PubMed ID: 11340607
[TBL] [Abstract][Full Text] [Related]
8. Molecular analysis of 13 cases of MLL/11q23 secondary acute leukemia and identification of topoisomerase II consensus-binding sequences near the chromosomal breakpoint of a secondary leukemia with the t(4;11).
Domer PH; Head DR; Renganathan N; Raimondi SC; Yang E; Atlas M
Leukemia; 1995 Aug; 9(8):1305-12. PubMed ID: 7643617
[TBL] [Abstract][Full Text] [Related]
9. [Therapy-related leukemia].
Yokozawa T; Naoe T
Nihon Naika Gakkai Zasshi; 2003 Jun; 92(6):1007-12. PubMed ID: 12866446
[No Abstract] [Full Text] [Related]
10. Etoposide metabolites enhance DNA topoisomerase II cleavage near leukemia-associated MLL translocation breakpoints.
Lovett BD; Strumberg D; Blair IA; Pang S; Burden DA; Megonigal MD; Rappaport EF; Rebbeck TR; Osheroff N; Pommier YG; Felix CA
Biochemistry; 2001 Feb; 40(5):1159-70. PubMed ID: 11170441
[TBL] [Abstract][Full Text] [Related]
11. Infant acute leukemias show the same biased distribution of ALL1 gene breaks as topoisomerase II related secondary acute leukemias.
Cimino G; Rapanotti MC; Biondi A; Elia L; Lo Coco F; Price C; Rossi V; Rivolta A; Canaani E; Croce CM; Mandelli F; Greaves M
Cancer Res; 1997 Jul; 57(14):2879-83. PubMed ID: 9230194
[TBL] [Abstract][Full Text] [Related]
12. Etoposide and illegitimate DNA double-strand break repair in the generation of MLL translocations: new insights and new questions.
Sung PA; Libura J; Richardson C
DNA Repair (Amst); 2006 Sep; 5(9-10):1109-18. PubMed ID: 16809075
[TBL] [Abstract][Full Text] [Related]
13. DNA topoisomerase II in therapy-related acute promyelocytic leukemia.
Mistry AR; Felix CA; Whitmarsh RJ; Mason A; Reiter A; Cassinat B; Parry A; Walz C; Wiemels JL; Segal MR; Adès L; Blair IA; Osheroff N; Peniket AJ; Lafage-Pochitaloff M; Cross NC; Chomienne C; Solomon E; Fenaux P; Grimwade D
N Engl J Med; 2005 Apr; 352(15):1529-38. PubMed ID: 15829534
[TBL] [Abstract][Full Text] [Related]
14. Therapy-related acute lymphoblastic leukaemia with MLL rearrangements following DNA topoisomerase II inhibitors, an increasing problem: report on two new cases and review of the literature since 1992.
Andersen MK; Christiansen DH; Jensen BA; Ernst P; Hauge G; Pedersen-Bjergaard J
Br J Haematol; 2001 Sep; 114(3):539-43. PubMed ID: 11552977
[TBL] [Abstract][Full Text] [Related]
15. HRX gene rearrangement in secondary acute lymphoblastic leukemia.
Kobayashi Y; Hayashi Y; Ozawa K; Asano S
Leuk Lymphoma; 1995 May; 17(5-6):391-9. PubMed ID: 7549829
[TBL] [Abstract][Full Text] [Related]
16. Topoisomerase II and leukemia.
Pendleton M; Lindsey RH; Felix CA; Grimwade D; Osheroff N
Ann N Y Acad Sci; 2014 Mar; 1310(1):98-110. PubMed ID: 24495080
[TBL] [Abstract][Full Text] [Related]
17. Secondary acute leukaemias with 11q23 rearrangement: clinical, cytogenetic, FISH and FICTION studies.
Zhang Y; Poetsch M; Weber-Matthiesen K; Rohde K; Winkemann M; Haferlach T; Gassmann W; Ludwig WD; Grote W; Löffler H; Schlegelberger B
Br J Haematol; 1996 Mar; 92(3):673-80. PubMed ID: 8616034
[TBL] [Abstract][Full Text] [Related]
18. Chromosome band 11q23 translocation breakpoints are DNA topoisomerase II cleavage sites.
Felix CA; Lange BJ; Hosler MR; Fertala J; Bjornsti MA
Cancer Res; 1995 Oct; 55(19):4287-92. PubMed ID: 7671237
[TBL] [Abstract][Full Text] [Related]
19. Mechanism of action of DNA topoisomerase inhibitors.
Binaschi M; Zunino F; Capranico G
Stem Cells; 1995 Jul; 13(4):369-79. PubMed ID: 7549896
[TBL] [Abstract][Full Text] [Related]
20. Topoisomerase II and the etiology of chromosomal translocations.
Felix CA; Kolaris CP; Osheroff N
DNA Repair (Amst); 2006 Sep; 5(9-10):1093-108. PubMed ID: 16857431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
